🇺🇸 FDA
Patent

US 11786517

Methods of treatment using a JAK inhibitor compound

granted A61KA61K31/4545A61K9/0019

Quick answer

US patent 11786517 (Methods of treatment using a JAK inhibitor compound) held by Theravance Biopharma R&D IP, LLC expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/4545, A61K9/0019, A61K9/0048, A61K9/0075